ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T

HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T

ESMO 2021: Novel Treatment Strategies in Advanced Urothelial Cancer

ESMO 2021 new treatments for advanced urothelial cancer targeted therapies for advanced urothelial cancer, antibody-drug conjugates for advanced urothelial cancer, , advanced urothelial cancer patients fit for cisplatin-based therapy